Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 9717023

Atrial flutter.

R W Campbell
View original source ↗Export metadata ↓

Abstract

Atrial flutter is a specific electrical entity. It has a now well-established mechanism involving a single macro-re-entrant circuit. Whilst many patients with atrial flutter may develop atrial fibrillation, atrial flutter deserves its own recognition and requires specific management. Acute termination by drugs is possible, although adding pacing improves efficacy. Ibutilide is a new intravenous therapy with considerable efficacy by with a risk of torsade de pointes. For long-term control, radiofrequency ablation is gradually supplanting chronic oral antiarrhythmic strategies.

Explore related subjects

Anti-Arrhythmia AgentsAtrial FlutterCardiac Pacing, ArtificialCatheter AblationElectrocardiographyHeart AtriaHumansPrognosisJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R W Campbell. 1998. Atrial flutter.. https://pubmed.ncbi.nlm.nih.gov/9717023/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2001

Permanent cardiac pacing versus medical treatment for the prevention of recurrent vasovagal syncope: a multicenter, randomized, controlled trial.

BACKGROUND: This clinical investigation was performed to compare the effects of permanent dual-chamber cardiac pacing with pharmacological therapy in patients with recurrent vasovagal syncope. METHODS AND RESULTS: Patients from 14 centers were randomized to receive either a DDD pacemaker provided with rate-drop response function or the beta-blocker atenolol at the dosage of 100 mg once a day. Inclusion criteria were age >35 years, >/=3 syncopal spells in the preceding 2 years, and positive response to tilt table testing with syncope occurring in association with relative bradycardia. The primary outcome was the first recurrence of syncope after randomization. Enrollment was started in December 1997, and the first formal interim analysis was performed on July 30, 2000. By that time, 93 patients (38 men and 55 women; mean age, 58.1+/-14.3 years) had been enrolled and randomized, although follow-up data were available for all patients (46 patients in the pacemaker arm, 47 patients in the pharmacological arm). The interim analysis showed a significant effect in favor of permanent cardiac pacing (recurrence of syncope in 2 patients [4.3%] after a median of 390 days) compared with medical treatment (recurrence of syncope in 12 patients [25.5%] after a median of 135 days; OR, 0.133; 95% CI, 0.028 to 0.632; P=0.004). Consequently, enrollment and follow-up were terminated. CONCLUSIONS: DDD pacing with rate-drop response function is more effective than beta-blockade for the prevention of syncopal recurrences in highly symptomatic vasovagal fainters with relative bradycardia during tilt-induced syncope.

Anti-Arrhythmia Agents↗
PubMed2001

[Protocols for the treatment of supraventricular tachycardias in the fetus].

The protocols mentioned are used by Utrecht University Hospital for the treatment of foetal supraventricular tachycardias. In the case of atrial flutters the pregnant woman is treated with sotalol administered orally and, if no sinus rhythm is obtained nor a reduced ventricular rhythm occurs, subsequently with digoxin. If there is no hydrops foetalis then this is also the treatment regimen for other forms of foetal supraventricular tachycardia. In the case of hydrops foetalis the treatment is more aggressive: digoxin intravenously or flecanide orally; if the rhythm does not convert into a sinus rhythm nor a reduced ventricular rhythm occurs then both of these medications are administered; if that also proves to be insufficient then direct foetal therapy can be considered.

Anti-Arrhythmia Agents↗
PubMed2001

[Ventricular tachycardia].

In patients with ventricular tachycardias, various structural and functional conditions can be influenced by certain triggers, initiating the mechanism of the arrhythmia. Thorough understanding of these different factors is paramount for the appropriate choice of treatment. Several options are available for the management of ventricular tachycardias: antiarrhythmic drugs, ICD implantation and catheter ablation or a combination of the above. The prognosis of an individual patient is determined by the underlying disease, the mechanism of tachycardia and the selected therapy. The complexity of several conditions requires a specialized diagnostic approach and tailored medical management. Therefore the patients with the following diagnoses should be referred to a specialized electrophysiology center: survivors of sudden cardiac death old infarct scar, reduced ejection fraction and complex ectopy Cardiomyopathy with syncope or ventricular tachycardias Long QT-Syndrome Brugada Syndrome Right Ventricular Dysplasia recurrent syncopes of unclear etiology.

Anti-Arrhythmia Agents↗